Piper Sandler analyst Edward Tenthoff downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight with a price target of $10.05, down from $12, after the company entered into am merger agreement whereby Concentra Biosciences will acquire iTeos for $10.047 in cash per share.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- Vor Bio appoints Cumbo, Detheux to board of directors
- iTeos Therapeutics Announces Merger with Concentra Biosciences
- iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR
- GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment
- GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab